Supernus resubmits NDA for SPN-830 apomorphine infusion for Parkinson's OFF episodes

SUPERNUS PHARMACEUTICALS, INC.

Resubmitted NDA for SPN-830 (apomorphine infusion device) to FDA for continuous treatment of OFF episodes in Parkinson's disease.
CRL in April 2024 identified two areas needing additional info; no clinical safety or efficacy issues were raised.
Company believes it has fully addressed the FDA's questions from the CRL.
If approved, SPN-830 could be an important novel therapy for Parkinson's patients.
Supernus will continue to work closely with the FDA during the NDA review process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.